Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Innate Pharma Stock Is Rocketing Higher Today

By Cory Renauer - Sep 17, 2021 at 1:21PM

Key Points

  • Innate Pharma stock jumped in response to positive data for monalizumab, an experimental cancer treatment being developed in partnership with AstraZeneca.
  • Monalizumab's results were overshadowed by another candidate from AstraZeneca.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A clinical trial with an experimental lung cancer drug produced some positive results.

What happened

Shares of Innate Pharma ( IPHA ), a clinical-stage biotechnology company, are rocketing higher in response to successful clinical-trial data for an experimental cancer drug called monalizumab. Investors surprised by the results pushed the stock 107.8% higher when the market opened today. Some of the enthusiasm later fizzled and the stock's gain was reduced to 43.7% as of 12:24 p.m. EDT on Friday.

So what 

Monalizumab is currently in a phase 2 trial called Coast, in combination with Imfinzi from AstraZeneca ( AZN -0.02% ). Imfinzi is approved to treat advanced-stage non-small cell lung cancer (NSCLC) patients with tumors that haven't grown since beginning standard first-line treatment.

Scientist presenting positive clinical trial data.

Image source: Getty Images.

Adding monalizumab to Imfinzi reduced patients' risk of disease progression or death by 35% compared to treatment with Imfinzi as a monotherapy.

Imfinzi and similar drugs that boost the immune system's ability to fight tumors can be highly effective for some patients, but most of the time they don't help at all. AstraZeneca and its big pharma peers are so eager to increase sales of their immunotherapies that they often shovel large sums of money at small biotechs with new drug candidates that could work well in combination.  

Now what

Unfortunately for Innate Pharma, the Coast trial also randomized patients to receive oleclumab. This is an experimental treatment from AstraZeneca with a different mode of action that appears to work even better than monalizumab. Adding oleclumab to Imfinzi reduced lung cancer patients' risk of disease progression or death by 56%.

AstraZeneca acquired full oncology rights to monalizumab back in 2018 and will continue developing it in partnership with Innate Pharma. The big pharma intends to begin a pivotal trial with Imfinzi plus monalizumab, but we don't know when. While AstraZeneca intends to develop both new cancer drug candidates, oleclumab will probably get a lot more attention. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Innate Pharma S.A. Stock Quote
Innate Pharma S.A.
IPHA
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.87 (-0.02%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
635%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.